newsfilter
← Latest News
PR Newswire·

Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates

FPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update Preliminary Phase 1 data for FPI-1434 expected to be reported at the Society of Nuclear Medicine and Molecular Imaging (SNMMI)